生物科技公司Parabilis Medicines (PBLS) 今日盘中股价大幅飙升66.75%，成为市场焦点。
消息面上，该公司于今日正式登陆美股市场进行首次公开募股（IPO），开盘后股价即大幅走高。Parabilis Medicines成立于2015年，专注于开发针对多种癌症及罕见肿瘤的治疗方案，此次IPO募集资金将主要用于推进其最领先的候选药物zolucatetide进入更后期的临床试验阶段，这增强了投资者对公司未来发展的信心。
根据公开信息，截至2025财年年末，Parabilis净亏损1.459亿美元，期末现金及现金等价物为2,770万美元。市场分析认为，尽管公司目前处于亏损状态，但其在癌症治疗领域的专业性和IPO带来的资金注入，为其后续的研发和商业化提供了关键支持，从而推动了股价的积极表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.